The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
Open accessAbstract
BACKGROUND & AIMS: Diagnostic criteria for metabolic associated fatty liver disease (MAFLD) have been proposed, but not validated. We aimed to compare the diagnostic accuracy of the MAFLD definition vs the existing NAFLD criteria to identify patients with significant fibrosis and to characterize the impact of mild alcohol intake. METHODS: We enrolled 765 Japanese patients with fatty liver (median age 54 years). MAFLD and NAFLD were diagnosed in 79.6% and 70.7% of patients respectively. Significant fibrosis was defined by FIB-4 index ≥1.3 and liver stiffness ≥6.6 kPa using shear wave elastography. Mild alcohol intake was defined as <20 g/day. Factors associated with significant fibrosis were analysed by logistic regression and decision-tree analyses. RESULTS: Liver stiffness was higher in MAFLD compared to NAFLD (7.7 vs 6.8 kPa, P = .0010). In logistic regression, MAFLD (OR 4.401; 95% CI 2.144-10.629; P < .0001), alcohol intake (OR 1.761; 95% CI 1.081-2.853; P = .0234), and NAFLD (OR 1.721; 95%CI 1.009-2.951; P = .0463) were independently associated with significant fibrosis. By decision-tree analysis, MAFLD, but not NAFLD or alcohol consumption was the initial classifier for significant fibrosis. The sensitivity for detecting significant fibrosis was higher for MAFLD than NAFLD (93.9% vs 73.0%). In patients with MAFLD, even mild alcohol intake was associated with an increase in the prevalence of significant fibrosis (25.0% vs 15.5%; P = .0181). CONCLUSIONS: The MAFLD definition better identifies a group with fatty liver and significant fibrosis evaluated by non-invasive tests. Moreover, in patients with MAFLD, even mild alcohol consumption is associated with worsening of hepatic fibrosis measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metabolic-associated fatty liver disease (MAFLD), is the most common finding in patients with TS.717”
From Clinical practice guidelines for the care of girls and women with Turner syndrome. (2024) · cites this paper as [717]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citationSterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · cited 4×
“ALT (U/L) 19 (14-29) 4-122 22 (16-33) 4-188 .”
InfluentialMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Griswold, M. G., Fullman, N., Hawley, C., Arian, N., Zimsen, S. R. M., Tymeson, H. D., Venkateswaran, V., Tapp, A. D., Forouzanfar, M. H., Salama, J. S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31310-2 · Cited by 3,524
Flagged first, then by citations
1 of the 38 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 401
Ciardullo, S., Carbone, M., Invernizzi, P., & Perseghin, G. (2022) · Hepatology Communications · doi:10.1002/hep4.1969 · Cited by 29
Seo, J. Y., Cho, E. J., Kim, M. J., Kwak, M., Yang, J. I., Chung, S. J., Yim, J. Y., Yoon, J. W., & Chung, G. E. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13099 · Cited by 29
Iwaki, M., Fujii, H., Hayashi, H., Toyoda, H., Oeda, S., Hyogo, H., Kawanaka, M., Morishita, A., Munekage, K., Kawata, K., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0515 · Cited by 30
Zaiou, M., Amrani, R., Rihn, B. H., & Hajri, T. (2021) · Biomedicines · doi:10.3390/biomedicines9091256 · Cited by 30
Fukunaga, S., Nakano, D., Tsutsumi, T., Kawaguchi, T., Eslam, M., Yoshinaga, S., Hirohiko, A. B. E., Nouno, R., Joh, S., Mitsuyama, K., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13795 · Cited by 29
Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm
Chua, D., Low, Z. S., Cheam, G. X., Ng, A. S., & Tan, N. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314762 · Cited by 30
Magherman, L., Parys, R. V., Pauwels, N., Verhelst, X., Devisscher, L., Vlierberghe, H. V., Geerts, A. M., & Lefere, S. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17388 · Cited by 28
Miwa, T., Francisque, C., Tajirika, S., Hanai, T., Imamura, N., Adachi, M., Horita, R., Menezes, L., Kawaguchi, T., Shimizu, M., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13906 · Cited by 27
Li, D., Cai, H., Liu, G., Han, Y., Qiu, K., Liu, W., Meng, K., & Yang, P. (2024) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-023-00982-6 · Cited by 30
Hatanaka, T., Kakizaki, S., Saito, N., Nakano, Y., Nakano, S., Hazama, Y., Yoshida, S., Hachisu, Y., Tanaka, Y., Kashiwabara, K., et al. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6574-20 · Cited by 29
Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update
Alharthi, J., & Eslam, M. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00248 · Cited by 28
MAFLD identifies patients with significant hepatic fibrosis better than MASLD
Pan, Z., Al‐Busafi, S. A., Abdulla, M., Fouad, Y. M., Sebastiani, G., & Eslam, M. (2024) · Hepatology International · doi:10.1007/s12072-024-10673-7 · Cited by 27
Li, D., Meng, K., Liu, G., Wen, Z., Han, Y., Liu, W., Xu, X. J., Song, L., Cai, H., & Yang, P. (2025) · Microbiome · doi:10.1186/s40168-025-02083-0 · Cited by 27
Hepatic Mitochondria-Gut Microbiota Interactions in Metabolism-Associated Fatty Liver Disease
Bellanti, F., Buglio, A. L., & Vendemiale, G. (2023) · Metabolites · doi:10.3390/metabo13030322 · Cited by 26
Zhang, R., Chen, Y., Zhang, J., & Liu, J. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002456 · Cited by 28
Metabolic dysfunction-associated fatty liver disease in people living with HIV
Michel, M. S., Labenz, C., Armandi, A., Kaps, L., Kremer, W. M., Galle, P. R., Grimm, D., Sprinzl, M. F., & Schattenberg, J. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-32965-y · Cited by 26
Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact
Tang, S.-Y., Tan, J. S., Pang, X. Z., & Lee, G. H. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i3.549 · Cited by 25
The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases
Tsutsumi, T., Nakano, D., Hashida, R., Sano, T., Kawaguchi, M., Amano, K., & Kawaguchi, T. (2023) · Nutrients · doi:10.3390/nu15051123 · Cited by 28
Colaci, C., Gambardella, M. L., Scarlata, G. G. M., Boccuto, L., Colica, C., Luzza, F., Scarpellini, E., Méndez‐Sánchez, N., & Abenavoli, L. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2023.134 · Cited by 27
Elsabaawy, M., Naguib, M., Abuamer, A., & Shaban, A. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01553-3 · Cited by 24
MAFLD associated with COPD via systemic inflammation independent of aging and smoking in men
Tsutsumi, T., Nakano, D., Kawaguchi, M., Hashida, R., Yoshinaga, S., Takahashi, H., Anzai, K., & Kawaguchi, T. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00887-w · Cited by 26
Yun, B., Ahn, S. H., Oh, J., Yoon, J., & Kim, B. K. (2022) · Hepatology Research · doi:10.1111/hepr.13830 · Cited by 24
Liu, Q., Fan, G., Bi, J., Qin, X., Fang, Q., Wu, M., Mei, S., Wan, Z., Lv, Y., Song, L., et al. (2023) · Environmental Research · doi:10.1016/j.envres.2023.117507 · Cited by 24
Sano, T., Amano, K., Ide, T., Isoda, H., Honma, Y., Morita, Y., Yano, Y., Nakamura, H., Itano, S., Miyajima, I., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13993 · Cited by 24
The NAFLD‐MAFLD debate: Is there a Consensus‐on‐Consensus methodology?
Fouad, Y. M., Dufour, J., Zheng, M., Bollipo, S. J., Desalegn, H., Grønbæk, H., & Gish, R. G. (2022) · Liver International · doi:10.1111/liv.15197 · Cited by 23
Zou, Y.-W., Li, Q., Gao, J., Pan, J., Ma, J., Chen, L., Lin, J., Mo, Y., Zhang, X., Liu, P., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.884636 · Cited by 23
Yang, Z., Gong, D., He, X., Huang, F., Sun, Y., & Hu, Q. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1113789 · Cited by 23
Kim, M. N., Han, K., Yoo, J., Hwang, S. G., Zhang, X., & Ahn, S. H. (2023) · International Journal of Cancer · doi:10.1002/ijc.34637 · Cited by 23
Feng, Z., Zhao, F., Wang, Z., Tang, X., Xie, Y., & Li, Q. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03192-0 · Cited by 25
Fukunaga, S., Mukasa, M., Nakane, T., Nakano, D., Tsutsumi, T., Chou, T., Tanaka, H., Hayashi, D., Minami, S., Ohuchi, A., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13973 · Cited by 24
Yang, R., Zou, Z., Zhong, B., Deng, H. X., He, F.-P., Shi, J., Zhao, C.-Y., Mi, Y., Zhou, Y., Di, F., et al. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.06.002 · Cited by 21
Yang, S., Cheng, J., Zhang, R., Sun, H., Zhang, H., Lyu, S., & Duan, W. (2021) · Hepatology Research · doi:10.1111/hepr.13728 · Cited by 21
The paradigm shift from NAFLD to MAFLD : A global primary care viewpoint
Farahat, T. M., Ungan, M., Vilaseca, J., Ponzo, J., Gupta, P. P., Schreiner, A. D., Sharief, W., Casler, K., Abdelkader, T., Abenavoli, L., et al. (2022) · Liver International · doi:10.1111/liv.15188 · Cited by 21
Guo, Y., Yang, J., Ma, R., Zhang, X., Guo, H., He, J., Wang, X., Cao, B., Maimaitijiang, R., Li, Y., et al. (2022) · Nutrients · doi:10.3390/nu14122361 · Cited by 21
Torres, L., Schuch, A., Longo, L., Valentini, B. B., Galvão, G. S., Luchese, E., Pinzon, C., Bartels, R., & Álvares‐da‐Silva, M. R. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100774 · Cited by 21
Liu, Q., Zhao, G., Li, Q., Wu, W., Zhang, Y., & Bian, H. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02576-4 · Cited by 21
Wang, S., Zhang, Q., & Qin, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-55282-4 · Cited by 24
Chen, Y., Chen, T., Yin, S., Huang, C., Huang, J., Lu, S., Yeh, M., Huang, C., Dai, C., Chen, Y., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16592 · Cited by 21
Wang, M.-F., Wan, B., Wu, Y., Huang, J., Zhu, Y., & Li, Y.-B. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i4.336 · Cited by 21
MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis
Huang, J., Xue, W., Wang, M.-F., Wu, Y., Singh, M., Zhu, Y., Kumar, R., & Lin, S. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s316096 · Cited by 21
MAFLD: Now is the time to capitalize on the momentum
Eslam, M., & George, J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.002 · Cited by 21
Devi, J. R., Raees, A., & Butt, A. S. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i1.158 · Cited by 20
Xie, X., Guo, B., Xiao, X., Yin, J., Wang, Z., Jiang, X., Li, J., Long, L., Zhou, J., Zhang, N., et al. (2022) · BMC Public Health · doi:10.1186/s12889-021-12486-x · Cited by 20
Lee, S. M., Cho, G. J., Wi, W. Y., Norwitz, E. R., Koo, B. K., Lee, J., Jung, Y. M., Kwak, S. H., Park, C., Jun, J. K., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10458-w · Cited by 20
Liu, H., Xing, Y., Nie, Q., Li, Z., Meng, C., & Ma, H. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s420872 · Cited by 20
MAFLD: A holistic view to redefining fatty liver disease
Eslam, M., & George, J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.027 · Cited by 20
Inamine, S., Kage, M., Akiba, J., Kawaguchi, T., Yoshio, S., Kawaguchi, M., Nakano, D., Tsutsumi, T., Hashida, R., & Oshiro, K. (2022) · Hepatology Research · doi:10.1111/hepr.13808 · Cited by 19
Chun, H. S., Lee, M., Lee, J. S., Lee, H. W., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., Lee, Y., Kim, J., et al. (2022) · Liver International · doi:10.1111/liv.15508 · Cited by 19
Zhang, W., Wang, X., Huang, J., Wang, S., Yao, Q., & Li, H. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1043901 · Cited by 19
Zhu, C., Ma, H., Huang, D., Li, G., Gao, J., Cai, M., You, H., Bu, L., & Qu, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.815995 · Cited by 20
Park, H., Yoon, E. L., Kim, M., Cho, S., Nah, E., & Jun, D. W. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.04.012 · Cited by 19
Liver Steatosis: A Marker of Metabolic Risk in Children
Neri, C. R., Scapaticci, S., Chiarelli, F., & Giannini, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094822 · Cited by 23
MAFLD: what 2 years of the redefinition of fatty liver disease has taught us
Grabherr, F., Grander, C., Effenberger, M., Schwärzler, J., & Tilg, H. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221139101 · Cited by 19
Yu, M., Lin, C., Liu, C., Wu, W., Hu, J., & Huang, Y. (2022) · Cancers · doi:10.3390/cancers14236012 · Cited by 18
Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis
Shi, Y., & Fan, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00822-1 · Cited by 19
Méndez‐Sánchez, N., & Díaz-Orozco, L. E. (2021) · Medical Science Monitor · doi:10.12659/msm.933860 · Cited by 18
Early-Life Exposure to Famine and Risk of Metabolic Associated Fatty Liver Disease in Chinese Adults
Liu, J., Wang, G., Wu, Y., Guan, Y., Luo, Z., Zhao, G., & Jiang, Y. (2021) · Nutrients · doi:10.3390/nu13114063 · Cited by 17
Wang, Q., Xue, J., Shi, M., Xie, Y., Xiao, H., Li, S., Lin, M. V., & Chi, X. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s369824 · Cited by 17
Body Composition Analysis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease
Onishi, S., Fukuda, A., Matsui, M., Ushiro, K., Nishikawa, T., Asai, A., Kim, S. K., & Nishikawa, H. (2023) · Nutrients · doi:10.3390/nu15183878 · Cited by 17
Ding, Y., Deng, Q., Yang, M., Niu, H., Wang, Z., & Xia, S. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s431251 · Cited by 23
What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications
Ramírez-Mejía, M. M., & Méndez‐Sánchez, N. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00620-9 · Cited by 17
Guo, Y., Hu, Y., Yang, J., Ma, R., Zhang, X., Guo, H., Wang, X., Li, Y., Peng, X., Zhang, S., et al. (2023) · European journal of medical research · doi:10.1186/s40001-023-01536-2 · Cited by 17
Kim, A. H., Son, D., & Lee, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1308265 · Cited by 17
Chang, Q., Zhang, Y., Zhang, T., Liu, Z., Cao, L., Zhang, Q., Liu, L., Sun, S., Wang, X., Zhou, M., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0133 · Cited by 18
Heo, J. H., Lee, M. Y., Kim, S. H., Zheng, M., Byrne, C. D., Targher, G., & Sung, K. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-558 · Cited by 17
Kim, M. N., Han, K., Yoo, J., Ha, Y., Chon, Y. E., Lee, J. H., Simon, T. G., Chan, A. T., & Hwang, S. G. (2021) · Scientific Reports · doi:10.1038/s41598-021-88733-3 · Cited by 17
Kemp, W. W., Clayton‐Chubb, D., Majeed, A., Glenister, K., Magliano, D. J., Lubel, J. S., Bourke, L., Simmons, D. S., & Roberts, S. K. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15723 · Cited by 17
From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
Gatzios, A., Rombaut, M., Buyl, K., De Kock, J., Rodrigues, R. M., Rogiers, V., Vanhaecke, T., & Boeckmans, J. (2022) · Biomedicines · doi:10.3390/biomedicines10010161 · Cited by 15
Ganesan, R., Gupta, H., Jeong, J., Sharma, S. P., Won, S., Oh, K., Yoon, S. J., Kim, D. J., & Suk, K. T. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121626 · Cited by 16
FGF21-mediated autophagy: Remodeling the homeostasis in response to stress in liver diseases
Shen, W., Yang, M., Chen, H., He, C., Li, H., Yang, X., Zhuo, J., Lin, Z., Hu, Z., Lü, D., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.05.019 · Cited by 16
Gu, D., Lu, Y., Xu, B., & Tang, X. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s437413 · Cited by 17
Nakane, T., Fukunaga, S., Nakano, D., Tsutsumi, T., Tanaka, H., Chou, T., Minami, S., Ohuchi, A., Nagata, T., Takaki, K., et al. (2023) · Hepatology Research · doi:10.1111/hepr.14010 · Cited by 16
Yan, J. Y., Zhou, J. F., Ding, Y., & Tu, C. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1340453 · Cited by 16
A call to action for fatty liver disease
Mantovani, A., & Valenti, L. V. C. (2021) · Liver International · doi:10.1111/liv.14907 · Cited by 16
The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting
Thrift, A. P., Nguyen, T. H.-A., Pham, C., Balakrishnan, M., Kanwal, F., Loomba, R. S., Duong, H. T., Ramsey, D. J., & El‐Serag, H. B. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.05.046 · Cited by 15
Otsubo, N., Fukuda, T., Cho, G., Ishibashi, F., Yamada, T., & Monzen, K. (2022) · Internal Medicine · doi:10.2169/internalmedicine.1097-22 · Cited by 15
Kang, M. K., Song, J. E., Loomba, R. S., Park, S. Y., Tak, W. Y., Kweon, Y. O., Lee, Y. R., & Park, J. G. (2024) · Scientific Reports · doi:10.1038/s41598-024-74287-7 · Cited by 16
Huang, J., Chang, T., Yeh, M., Shen, F., Tai, C., Chen, J., Huang, Y., Hsu, C., Cheng, P., Lin, C., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000571 · Cited by 15
Katsiki, N., Kolovou, G. D., & Vrablı́k, M. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02181-9 · Cited by 15
Pan, Z., Fan, J., & Eslam, M. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.07.007 · Cited by 16
MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients
Meroni, M., Longo, M., Paolini, E., Lombardi, R., Piciotti, R., Francione, P., Badiali, S., Maggioni, M., Fracanzani, A. L., & Dongiovanni, P. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13396 · Cited by 15
Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities
Du, X., DeForest, N., & Majithia, A. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.777075 · Cited by 17
MAFLD and Cardiovascular Events: What Does the Evidence Show?
George, J., Gish, R. G., & Geier, A. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.02.027 · Cited by 15
Health-care provision and policy for non-alcoholic fatty liver disease in sub-Saharan Africa
Spearman, C. W., Abdo, A., Ambali, A., Awuku, Y. A., Kassianides, C., Lesi, O. A., Ndomondo-Sigonda, M., Onyekwere, C. A., Rwegasha, J., Shewaye, A. B., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00296-x · Cited by 15
Wang, Y., Shen, R., & Ge, J. (2022) · Sleep Medicine · doi:10.1016/j.sleep.2022.11.029 · Cited by 14
Lei, F., Wang, X., Wang, C., Huang, X., Liu, Y.-M., Qin, J., Zhang, P., Ji, Y., She, Z., Cai, J., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1109673 · Cited by 14
Yu, G., Liu, L., Qin, T., Luo, Y., Song, C., Chen, X., Duan, H., Jiang, Y., Zeng, H., Wan, H., et al. (2023) · Biological Trace Element Research · doi:10.1007/s12011-023-03666-4 · Cited by 14
Miwa, T., Tajirika, S., Hanai, T., Imamura, N., Adachi, M., Horita, R., Fukao, T., Shimizu, M., & Yamamoto, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-52797-8 · Cited by 15
Park, H. J., Lee, S., & Lee, J. S. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04285-w · Cited by 14
Cao, W., Xu, Y., Shen, Y., Wang, Y., Ma, X., & Bao, Y. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0559 · Cited by 14
Xiong, K.-G., Ke, K.-Y., Chen, L.-F., Kong, J., Lin, T.-S., Lin, Q.-B., Lin, S., & Zhu, Y. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.04.001 · Cited by 14
Fouad, Y. M., Palmer, M., Landgren, H., Karsdal, M. A., (10670712), M. B., (2393065), D. A. S., Gruss, H.-J., Sheikh, M. Y., Attia, D. I., Bollipo, S. J., et al. (2022) · Figshare · Cited by 14
Dai, X., Zhou, G., & Xu, L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279274 · Cited by 14
Hashida, R., Nakano, D., Yamamura, S., Kawaguchi, T., Tsutsumi, T., Matsuse, H., Takahashi, H., Gerber, L. H., Younossi, Z. M., & Torimura, T. (2021) · Life · doi:10.3390/life11080799 · Cited by 13
Fouad, Y., Palmer, M., Chen, M., Regev, A., Banerjee, R., Myers, R., Riccio, R., Torstenson, R., Younes, R., Arora, P. S., et al. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00408 · Cited by 16
The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease
Kulkarni, A. V., & Sarin, S. K. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231178370 · Cited by 13
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
Suoh, M., Esmaili, S., Eslam, M., & George, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10731-0 · Cited by 15
Lim, T. S., Chun, H. S., Kim, S. S., Kim, J. K., Lee, M., Cho, H. J., Kim, S. U., & Cheong, J. Y. (2023) · Gut and Liver · doi:10.5009/gnl220400 · Cited by 13
Pelusi, S., Bianco, C., Colombo, M., Cologni, G., Poggio, P. D., Pugliese, N., Prati, D., Pigozzi, M. G., D’Ambrosio, R., Lampertico, P., et al. (2023) · Liver International · doi:10.1111/liv.15577 · Cited by 13
Miyake, T., Matsuura, B., Furukawa, S., Ishihara, T., Yoshida, O., Miyazaki, M., Watanebe, K., Shiomi, A., Nakaguchi, H., Yamamoto, Y., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13772 · Cited by 12
Metadata
- Authors
- Yamamura, S., Eslam, M., Kawaguchi, T., Tsutsumi, T., Nakano, D., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., & Torimura, T.
- Affiliations
- Kurume University (JP)
- The University of Sydney (AU)
- Medical Examination Section Medical Examination Part Facilities Public Utility Foundation Saga Prefectural Health Promotion Foundation Saga Japan
- Saga University (JP)
- Corresponding author
- Yamamura, Sakura
- Eslam, Mohammed
- ORCID
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2020-11-30
- Volume
- 40
- Issue
- 12
- Pages
- 3018-3030
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W3089758949
- Cited by
- 401
- References
- 38
- Citations by year
- 2026: 10 · 2025: 33 · 2024: 85 · 2023: 96 · 2022: 84 · 2021: 84 · 2020: 6
- FWCI
- 48.37
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Liver International (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (acceptedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- Japan Agency for Medical Research and Development (JP20fk0210040)
- Research and Development
- Medical Foundation (APP1107178, APP1108422)
- University of Sydney
- Medical Research Council
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- metabolic-associated fatty liver disease, non-alcoholic fatty liver disease, liver fibrosis, diagnostic accuracy, liver stiffness, shear wave elastography, FIB-4, hepatic steatosis, noninvasive fibrosis assessment
- MeSH terms
- Humans, Liver Cirrhosis, Middle Aged, Prevalence, Logistic Models, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
